Ropinirole and pramipexole, the new agonists
Identifieur interne : 000D40 ( PascalFrancis/Corpus ); précédent : 000D39; suivant : 000D41Ropinirole and pramipexole, the new agonists
Auteurs : D. E. Hobson ; E. Pourcher ; W. R. W. MartinSource :
- Canadian journal of neurological sciences [ 0317-1671 ] ; 1999.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
|
---|
Format Inist (serveur)
NO : | PASCAL 99-0456205 INIST |
---|---|
ET : | Ropinirole and pramipexole, the new agonists |
AU : | HOBSON (D. E.); POURCHER (E.); MARTIN (W. R. W.) |
AF : | University of Manitoba/Winnipeg, Manitoba/Canada (1 aut.); Laval University/Quebec City, Quebec/Canada (2 aut.); University of Alberta/Edmonton, Alberta/Canada (3 aut.) |
DT : | Publication en série; Niveau analytique |
SO : | Canadian journal of neurological sciences; ISSN 0317-1671; Coden CJNSA2; Canada; Da. 1999; Vol. 26; No. SUP2; S27-S33; Abs. français; Bibl. 53 ref. |
LA : | Anglais |
CC : | 002B02B06; 002B17G |
FD : | Parkinson maladie; Ropinirole; Agoniste; Récepteur dopaminergique D2; Pramipexole; Antiparkinsonien; Chimiothérapie; Traitement; Homme |
FG : | Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative |
ED : | Parkinson disease; Ropinirole; Agonist; D2 Dopamine receptor; Pramipexole; Antiparkinson agent; Chemotherapy; Treatment; Human |
EG : | Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease |
SD : | Parkinson enfermedad; Ropinirol; Agonista; Receptor dopaminérgico D2; Pramipexol; Antiparkinsoniano; Quimioterapia; Tratamiento; Hombre |
LO : | INIST-17449.354000089421960050 |
ID : | 99-0456205 |
Links to Exploration step
Pascal:99-0456205Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Ropinirole and pramipexole, the new agonists</title>
<author><name sortKey="Hobson, D E" sort="Hobson, D E" uniqKey="Hobson D" first="D. E." last="Hobson">D. E. Hobson</name>
<affiliation><inist:fA14 i1="01"><s1>University of Manitoba</s1>
<s2>Winnipeg, Manitoba</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pourcher, E" sort="Pourcher, E" uniqKey="Pourcher E" first="E." last="Pourcher">E. Pourcher</name>
<affiliation><inist:fA14 i1="02"><s1>Laval University</s1>
<s2>Quebec City, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martin, W R W" sort="Martin, W R W" uniqKey="Martin W" first="W. R. W." last="Martin">W. R. W. Martin</name>
<affiliation><inist:fA14 i1="03"><s1>University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">99-0456205</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 99-0456205 INIST</idno>
<idno type="RBID">Pascal:99-0456205</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D40</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Ropinirole and pramipexole, the new agonists</title>
<author><name sortKey="Hobson, D E" sort="Hobson, D E" uniqKey="Hobson D" first="D. E." last="Hobson">D. E. Hobson</name>
<affiliation><inist:fA14 i1="01"><s1>University of Manitoba</s1>
<s2>Winnipeg, Manitoba</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Pourcher, E" sort="Pourcher, E" uniqKey="Pourcher E" first="E." last="Pourcher">E. Pourcher</name>
<affiliation><inist:fA14 i1="02"><s1>Laval University</s1>
<s2>Quebec City, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Martin, W R W" sort="Martin, W R W" uniqKey="Martin W" first="W. R. W." last="Martin">W. R. W. Martin</name>
<affiliation><inist:fA14 i1="03"><s1>University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Canadian journal of neurological sciences</title>
<title level="j" type="abbreviated">Can. j. neurol. sci.</title>
<idno type="ISSN">0317-1671</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Canadian journal of neurological sciences</title>
<title level="j" type="abbreviated">Can. j. neurol. sci.</title>
<idno type="ISSN">0317-1671</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Agonist</term>
<term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>D2 Dopamine receptor</term>
<term>Human</term>
<term>Parkinson disease</term>
<term>Pramipexole</term>
<term>Ropinirole</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Ropinirole</term>
<term>Agoniste</term>
<term>Récepteur dopaminergique D2</term>
<term>Pramipexole</term>
<term>Antiparkinsonien</term>
<term>Chimiothérapie</term>
<term>Traitement</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0317-1671</s0>
</fA01>
<fA02 i1="01"><s0>CJNSA2</s0>
</fA02>
<fA03 i2="1"><s0>Can. j. neurol. sci.</s0>
</fA03>
<fA05><s2>26</s2>
</fA05>
<fA06><s3>SUP2</s3>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Ropinirole and pramipexole, the new agonists</s1>
</fA08>
<fA09 i1="01" i2="1" l="ENG"><s1>Parkinson's Disease: Challenges and New Advances: Presentations of a series of regional educational programs in 1998</s1>
</fA09>
<fA11 i1="01" i2="1"><s1>HOBSON (D. E.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>POURCHER (E.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MARTIN (W. R. W.)</s1>
</fA11>
<fA14 i1="01"><s1>University of Manitoba</s1>
<s2>Winnipeg, Manitoba</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Laval University</s1>
<s2>Quebec City, Quebec</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of Alberta</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s2>S27-S33</s2>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA24 i1="01"><s0>fre</s0>
</fA24>
<fA43 i1="01"><s1>INIST</s1>
<s2>17449</s2>
<s5>354000089421960050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 1999 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>53 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>99-0456205</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Canadian journal of neurological sciences</s0>
</fA64>
<fA66 i1="01"><s0>CAN</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02B06</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Ropinirole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Ropinirol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Agoniste</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Agonist</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Agonista</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s5>06</s5>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Pramipexole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Pramipexole</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Pramipexol</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>16</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>16</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>291</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 99-0456205 INIST</NO>
<ET>Ropinirole and pramipexole, the new agonists</ET>
<AU>HOBSON (D. E.); POURCHER (E.); MARTIN (W. R. W.)</AU>
<AF>University of Manitoba/Winnipeg, Manitoba/Canada (1 aut.); Laval University/Quebec City, Quebec/Canada (2 aut.); University of Alberta/Edmonton, Alberta/Canada (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Canadian journal of neurological sciences; ISSN 0317-1671; Coden CJNSA2; Canada; Da. 1999; Vol. 26; No. SUP2; S27-S33; Abs. français; Bibl. 53 ref.</SO>
<LA>Anglais</LA>
<CC>002B02B06; 002B17G</CC>
<FD>Parkinson maladie; Ropinirole; Agoniste; Récepteur dopaminergique D2; Pramipexole; Antiparkinsonien; Chimiothérapie; Traitement; Homme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Ropinirole; Agonist; D2 Dopamine receptor; Pramipexole; Antiparkinson agent; Chemotherapy; Treatment; Human</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Ropinirol; Agonista; Receptor dopaminérgico D2; Pramipexol; Antiparkinsoniano; Quimioterapia; Tratamiento; Hombre</SD>
<LO>INIST-17449.354000089421960050</LO>
<ID>99-0456205</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D40 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000D40 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= PascalFrancis |étape= Corpus |type= RBID |clé= Pascal:99-0456205 |texte= Ropinirole and pramipexole, the new agonists }}
This area was generated with Dilib version V0.6.29. |